VItamiN D replacement to prevent Acute Lung injury following OesophagectOmy (VINDALOO-2) | Not Recruiting
VItamiN D replacement to prevent Acute Lung injury following OesophagectOmy (VINDALOO-2)
Trial Source

There is no location for this trial

Location data is sourced from multiple external providers and UKCTG is not responsible for and cannot guarantee the accuracy of data.

Health Conditions
  • Oesphageal cancer, acute lung injury
Dr David Thickett
+44 (0)121 472 1311 (ext: 8289)
See all trial contact details
Primary Contact Details
Not Recruiting
Recruitment Status
Primary Trial ID Number
Not provided at time of registration
Research Details
  • This is a randomised double-blind placebo-controlled study to test the safety and efficacy of rapid vitamin D replacement upon extravascular lung water and markers of alveolar/systemic inflammation in patients undergoing oesophagectomy. The pilot study was registered in September 2011:
Sorry, this information is not available
Study Design
Randomised placebo-controlled phase II study
Study Type

Oral vitamin D liquid (100,000 IU) versus identical placebo

Intervention Type
Primary Outcome Measures
  • Extravascular lung water index (EVLWI) at the end of oesophagectomy
Secondary Outcome Measures
  • Clinical markers indicative of lung injury:
  • 1. P:F ratio
  • 2. Oxygenation index
  • 3. Development of lung injury / ARDS day 0-28
  • 4. Duration of ventilation and organ failure, survival
  • 5. Safety and tolerability of vitamin D supplementation
  • 6. Plasma indices of endothelial and alveolar epithelial function/ injury
  • 7. Plasma inflammatory response
  • 8. Plasma LL-37 levels
  • 9. Plasma vitamin D status (25D3, 1,25D3 and VDBP)
  • 10. EVLWI post-operative day 1
2013 protocol in:
Result Reports
Sorry, this information is not available
Age Range
Who Can Participate
Number of Participants
Participant Inclusion Criteria
  • 1. Planned transthoracic oesophagectomy for oesophageal carcinoma at a participating centre
  • 2. Aged over 18 years on day of first dose of investigational medicinal product (IMP)
  • 3. Ability to give written informed consent to participate in the study
Participant Exclusion Criteria
  • 1. Known intolerance of vitamin D
  • 2. Known sarcoidosis, hyperparathyroidism, or nephrolithiasis
  • 3. Taking more than 1000iu/day vitamin D supplementation in the month preceding enrolment
  • 4. Baseline serum corrected calcium >2.65 mmol/L
  • 5. Undergoing haemodialysis
  • 6. Pregnant or breastfeeding
  • 7. Taking cardiac glycoside, carbamazepine, phenobarbital, phenytoin, primidone or long-term immunosuppressant therapy
  • 8. Taking oral preparation containing > 10 micrograms vitamin D/day up to 2 months before first dose of IMP
  • 9. Diagnosis of COPD with an FEV1 less than 50% predicted or resting oxygen saturations of less 92%
Trial Location(s)
Cancer Research UK Clinical Trials Unit - Birmingham
B15 2TT
Trial Contact(s)
Primary Trial Contact
Dr David Thickett
+44 (0)121 472 1311 (ext: 8289)
Other Trial Contacts
Sorry, this information is not available
Countries Recruiting
United Kingdom
Scientific Title
Vitamin D replacement to prevent acute lung injury following oesophagectomy - a randomised placebo controlled trial
EudraCT Number
Sorry, this information is not available
  • Medical Research Council UK (MRC) ref: G1100196
Other Study ID Numbers
version 1 3-3-2011
University of Birmingham (UK)
Key Dates

Recruitment Start Date

01 Apr 2012

Recruitment End Date

01 Apr 2014

Trial Start Date

01 Apr 2012

Trial End Date

01 Apr 2014

Date Assigned

21 Dec 2011

Last Updated

31 Mar 2015